The advantages of fentanyl for the treatment of pain: Studies of pharmacological profiles and fentanyl relatedside effects

Arief Nurrochmad, Ozaki Masahiko, Minoru Narita, Tsutomu Suzuki


The understanding of the pharmacological profiles of fentanyl and fentanyl-related side effects seems to be critical for the management for control of pain. Therefore, the present study was designed to investigate the advantages for treatment with fentanyl and the side effects such as emesis and gastrointestinal transit inhibition. The results demonstrated that fentanyl produced a profound antinociception in ferrets and mice than that induced by morphine. These findings are consistent with the experiences in the clinic. Morphine with lower doses than antinociceptive doses, produced a significant increase in gastrointestinal transit inhibition. However, fentanyl produced no gastrointestinal transit inhibition unlike morphine. These findings are consistent with the clinical experiences in the use of fentanyl. The clinical studies in patients chronic cancer pain showed that transdermal therapeutic delivery system for fentanyl (TTS-fentanyl) produces less side effects such as constipation, nausea and vomiting than that induced by oral morphine. Morphine with lower doses than that used for antinociceptive assay also produced either in the number of retching or vomiting. However, fentanyl failed to produce emetic response in ferrets. These findings indicate that fentanyl produces much less emesis than that induced by morphine. Finally, we conclude that fentanyl produced potent antinociception in ferrets and mice. In addition, fentanyl produced much less side effects including emesis and constipation. These findings may provide evidence for benefit and usefulness of fentanyl for clinical frame on the management of pain treatment.
Key word: fentanyl; antinociception; emesis; ferret.

Full Text:



Ahmedzai, S. and Brooks, D., 1997, Transdermal fentanyl versus sustained-release oral morphine in cancer pain: preference, efficacy, and quality of life. The TTS-Fentanyl Comparative Trial Group, J Pain Symptom Manage 13: 254-261.

Anonym, 1999, ASHP therapeutic guidelines on the pharmacologic management of nausea and vomiting in adultand pediatric patients receiving chemotheraphy or radiation theraphy or undergoing surgery, Am J Health Syst Pharm 56: 729-764.

Aparasu, R., McCoy, R.A., Weber, C., Mair, D., and Parasuraman, T.V., 1999, Opioid-induced emesis among hospitalized nonsurgical patients: effect on pain and quality of life, J Pain Symptom Manage 18: 280-288.

Barnes, N.M., Bunce, K.T., Naylor, R.J., and Rudd, J.A., 1991, The actions of fentanyl to inhibit drug-induced emesis, Neuropharmacology 30: 1073-1083.

Donner, B. and Zenz, M., 1995, Transdermal fentanyl: a new step on the therapeutic ladder, Anticancer Drugs 6: 39-43.

Donner, B., Zenz, M., Tryba, M., and Strumpf, M., 1996, Direct conversion from oral morphine to transdermal fentanyl: a multicenter study in patients with cancer pain, Pain 64: 527-534.

Fallon, M. and O'Neill B., 1997, ABC of palliative care, Constipation and diarrhoea, BMJ 315: 1293-1296.

Fallon, M.T. and Hanks, G.W., 1999, Morphine, constipation and performance status in advanced cancer patients, Palliat Med 13: 159-160.

Kamei, J., Ohsawa, M., Misawa, M., Nagase, H., and Kasuya, Y., 1995, Effect of diabetics on the morphine-induced inhibition of gastrointestinal transit, Jpn. J. Psychopharmacol 15: 165-169.

Marrow, G.R., Roscoe, J.A., and Hickok, J.T., 1998, Initial control of chemotherapy-induced nausea and vomiting in patient quality of life, Oncology 12: 32-37.

Megens, A.A., Artois, K., Vermeire, J., Meert, T., and Awouters, F.H., 1998, Comparison of the analgesic and intestinal effects of fentanyl and morphine in rats, J Pain Symptom Manage 15: 253-257.

Oettle, H., and Riess, H., 2001, Treatment of chemotherapy-induced nausea and vomiting J Cancer Res Clin Oncol 127: 340-345.

Payne, R., Mathias, S.D., Pasta, D.J., Wanke, L.A., Williams, R., and Mahmoud, R., 1998., Quality of life and cancer pain: satisfaction and side effects with transdermal fentanyl versus oral morphine, J Clin Oncol 16: 1588-1593.

Radbruch, L., Sabatowski, R., Loick, G., Kulbe, C., Kasper, M., Grond, S., and Lehmann, K.A., 2000, Constipation and the use of laxatives: a comparison between transdermal fentanyl and oral morphine, Palliat Med 14: 111-119.

Rudd, J.A., Jordan, C.C., and Naylor, R.J., 1994, Profiles of emetic action of cisplatin in the ferret: a potential model of acute and delayed emesis, Eur J Pharmacol 262: R1-2.

Tarumi, Y., 2002, Clinical implication of opioid rotation: The 23rd JNRC Proceedings Neurobiology of Opioid Receptor Symposium Abstract Book: 172-177.

Thomson, P.I., Bingham, S., Andrews, P.L.R., Patel, N., Joel, S.P., and Slevin, M.L., 1992, Morphine 6-glucoronide: a metabolite of morphine with greater emetic potency than morphine in the ferret, Br J Pharmacol 106: 3-8.

Urie, J., Fielding, H., McArthur, D., Kinnear, M., Hudson, S., and Fallon, M., 2000, Palliative care. Pharm J 265: 603-614.



  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

Indonesian J Pharm indexed by:

analytics View My Stats